EUVIMEDEUVIMED entdecken
Open Access

Canagliflozin Alleviates Experimental ANCA-Associated Vasculitis through Suppression of Pathogenic T-Cell Responses

Xiang-Yu Han iD, Zhi-Ying Li iD, Su-Fang Chen iD, Ming-Hui Zhao, Mark A Little, Min Chen iD

Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2407-2420

DOI: 10.1681/asn.0000001137 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 26.05.2026. Verfasst von Xiang-Yu Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China. Hauptthemen laut MEDLINE: Canagliflozin, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sodium-Glucose Transporter 2 Inhibitors, T-Lymphocytes. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Capital's Funds for Health Improvement and Research, National key research and development program, National Natural Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Canagliflozin ameliorated experimental ANCA-associated vasculitis through broad suppression of pathogenic T-cell subsets. The immunomodulatory effect of canagliflozin was mediated in part by inhibition of p38 mitogen-activated protein kinase signaling in T cells.

Background

The nephroprotective role of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been well established by several randomized controlled trials involving patients with diabetic and nondiabetic CKD. However, the impact of SGLT2 inhibitors on ANCA-associated vasculitis (AAV) and the underlying mechanisms remain unclear.

Methods

The therapeutic effects of canagliflozin were evaluated in a rat model of experimental AAV. RNA sequencing was performed on the kidney and lymph nodes. In parallel, mechanistic studies were conducted in mouse models. Myeloperoxidase-deficient ( Mpo −/− ) mice were immunized with mouse myeloperoxidase and treated with canagliflozin. Splenocytes from these donors were then adoptively transferred into recombinase-activating gene-1–deficient ( Rag1 −/− ) mice. Comprehensive immune phenotyping by flow cytometry, enzyme-linked immunospot assays, and in vitro differentiation of human T cells were employed to dissect the immunomodulatory effects and underlying mechanisms.

Results

Canagliflozin alleviated kidney injury, pulmonary hemorrhage, and T-lymphocyte infiltration in AAV rats. Renal transcriptomic analysis showed a suppression of adaptive immunity pathways. In the adoptive transfer model, canagliflozin treatment of donor mice led to a significant reduction in splenic Th1, Th17, and CD8 + T cells, accompanied by a markedly diminished capacity of splenocytes to secrete IFN- γ and IL-17A upon restimulation. Transfer of these modulated splenocytes conferred significant nephroprotection to recipient mice. In vitro , canagliflozin suppressed the differentiation of primary CD4 + T cells from patients with AAV into both Th1 and Th17 lineages, but did not directly affect B-cell activation or antibody production. Mechanistically, canagliflozin inhibited the phosphorylation of both p38 and extracellular signal-regulated kinase mitogen-activated protein kinases in activated T cells, and the suppressive effect on cytokine production was partially reversed by activation of the p38 mitogen-activated protein kinase pathway.

Conclusions

Canagliflozin alleviated experimental AAV by suppressing pathogenic T cell effector responses—an effect mechanistically linked to inhibition of the p38 signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisSodium-Glucose Transporter 2 InhibitorsT-LymphocytesAnimalsMiceRatsp38 Mitogen-Activated Protein KinasesHumansDisease Models, AnimalMale

Stichwörter der Autor:innen

ANCASGLT2 inhibitorsimmunology

Substanzen

Canagliflozinp38 Mitogen-Activated Protein KinasesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
  • Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
  • Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
  • Trinity Kidney Centre, Trinity Translational Medicine Institute, School of Medicine, Trinity College Dublin, Dublin, Ireland.
  • State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.

ORCID-Profile: Xiang-Yu Han, Zhi-Ying Li, Su-Fang Chen, Min Chen

Förderung

  • Capital's Funds for Health Improvement and Research
  • National key research and development program
  • National Natural Science Fund
  • Peking University Clinical Scientist Training Program
  • Beijing Physician Scientist Training Project
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Han, X. Y., Li, Z. Y., Chen, S. F., Zhao, M. H., Little, M. A., & Chen, M. (2026). Canagliflozin Alleviates Experimental ANCA-Associated Vasculitis through Suppression of Pathogenic T-Cell Responses. Journal of the American Society of Nephrology, 37(11), 2407-2420. https://doi.org/10.1681/asn.0000001137

Vancouver

Han XY, Li ZY, Chen SF, Zhao MH, Little MA, Chen M. Canagliflozin Alleviates Experimental ANCA-Associated Vasculitis through Suppression of Pathogenic T-Cell Responses. Journal of the American Society of Nephrology. 2026;37(11):2407-2420. doi:10.1681/asn.0000001137

BibTeX
@article{Han2026,
  author = {Han, Xiang-Yu and Li, Zhi-Ying and Chen, Su-Fang and Zhao, Ming-Hui and Little, Mark A and Chen, Min},
  title = {Canagliflozin Alleviates Experimental ANCA-Associated Vasculitis through Suppression of Pathogenic T-Cell Responses},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {11},
  pages = {2407--2420},
  doi = {10.1681/asn.0000001137}
}
Kostenlos starten →